Evidence-based Treatment for Psoriasis Erythroderma_West China Medical Journal

Authors：

WEN Xiang , ZHOU Rongying , HAO Dan ,  JIANG Xian.

Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

JIANG Xian., Email: 419aaa@gmail.com

Keywords：

紅皮病型銀屑病; 循證治療; 環孢素; 甲氨蝶呤

DOI：

10.7507/1002-0179.20130592

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　為紅皮病型銀屑病患者制定循證治療方案。方法　 2012年3月收治1例紅皮病型銀屑病患者，充分評估患者情況后，提出臨床問題，計算機檢索Cochrane圖書館、 Medline、中文全文期刊醫學數據庫中相關研究，根據檢索結果結合患者實際情況，制定治療方案。結果　共檢索到相關文獻3篇。通過對檢索結果進行分析，并結合患者意愿，為患者制定了采用甲氨喋呤的治療方案。經過6個月的治療隨訪，證實該方案適合該患者。結論　采用循證醫學的方法，為紅皮病型銀屑病患者制定合理的治療方案，可提高療效。

Citation： WEN Xiang,ZHOU Rongying,HAO Dan,JIANG Xian.. Evidence-based Treatment for Psoriasis Erythroderma. West China Medical Journal, 2013, 28(12): 1877-1888. doi: 10.7507/1002-0179.20130592 Copy

1.	趙辯. 中國臨床皮膚病學[M]. 南京: 江蘇科學技術出版社, 2002: 867.
2.	鄧丙戌. 銀屑病[M]. 北京: 科學技術文獻出版社, 2003: 701.
3.	李新宇. 抗銀屑病藥物研究的動向和未來[J]. 國外醫學·皮膚性病學分冊, 1997, 23(1): 17-21.
4.	孫建方. 膿皰型及紅皮病型銀屑病[J]. 國外醫學·皮膚性病學分冊, 1997, 23(1): 40-44.
5.	Flytström I, Stenberg B, Svensson A, et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial[J]. Br J Dermatol, 2008, 158(1): 116-121.
6.	沈軍. 甲氨蝶呤與環孢素治療銀屑病的療效對比分析[J]. 中國社區醫師(醫學專業半月刊), 2008, 10(24): 58.
7.	Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis[J]. N Engl J Med, 2003, 349(7): 658-665.
8.	邵長庚. 銀屑病臨床試驗的設計和實際應用中的問題[J]. 臨床皮膚科雜志, 2005, 34(2): 127-129.
9.	Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis[J]. J Am Acad Dermatol, 2005, 53(4): 652-659.
10.	Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis[J]. Clin Drug Investig, 2010, 30(2): 101-108.
11.	Baggott JE, Oster RA, Tamura T. Meta-analysis of cancer risk in folic acid supplementation trials[J]. Cancer Epidemiol, 2012, 36(1): 78-81.
12.	Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies[J]. Clin Dermatol, 2010, 28(1): 88-92.
13.	Atkinson K, Biggs J, Darveniza P, et al. Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation[J]. N Engl J Med, 1984, 310(8): 527.
14.	Melnikov S, Mayan H, Uchida S, et al. Cyclosporine metabolic side effects: association with the WNK4 system[J]. Eur J Clin Invest, 2011, 41(10): 1113-1120.
15.	Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure[J]. Cochrane Database Syst Rev, 2010, 20(1): CD007893.
16.	Dehesa L, Abuchar A, Nuno-Gonzalez A, et al. The use of cyclosporine in dermatology[J]. J Drug Dermatol, 2012, 11(8): 979.
17.	Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference[J]. J Am Acad Dermatol, 2010, 62(5): 838-853.

1. 　趙辯. 中國臨床皮膚病學[M]. 南京: 江蘇科學技術出版社, 2002: 867.
2. 　鄧丙戌. 銀屑病[M]. 北京: 科學技術文獻出版社, 2003: 701.
3. 　李新宇. 抗銀屑病藥物研究的動向和未來[J]. 國外醫學·皮膚性病學分冊, 1997, 23(1): 17-21.
4. 　孫建方. 膿皰型及紅皮病型銀屑病[J]. 國外醫學·皮膚性病學分冊, 1997, 23(1): 40-44.
5. 　Flytström I, Stenberg B, Svensson A, et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial[J]. Br J Dermatol, 2008, 158(1): 116-121.
6. 　沈軍. 甲氨蝶呤與環孢素治療銀屑病的療效對比分析[J]. 中國社區醫師(醫學專業半月刊), 2008, 10(24): 58.
7. 　Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis[J]. N Engl J Med, 2003, 349(7): 658-665.
8. 　邵長庚. 銀屑病臨床試驗的設計和實際應用中的問題[J]. 臨床皮膚科雜志, 2005, 34(2): 127-129.
9. 　Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis[J]. J Am Acad Dermatol, 2005, 53(4): 652-659.
10. 　Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis[J]. Clin Drug Investig, 2010, 30(2): 101-108.
11. 　Baggott JE, Oster RA, Tamura T. Meta-analysis of cancer risk in folic acid supplementation trials[J]. Cancer Epidemiol, 2012, 36(1): 78-81.
12. 　Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies[J]. Clin Dermatol, 2010, 28(1): 88-92.
13. 　Atkinson K, Biggs J, Darveniza P, et al. Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation[J]. N Engl J Med, 1984, 310(8): 527.
14. 　Melnikov S, Mayan H, Uchida S, et al. Cyclosporine metabolic side effects: association with the WNK4 system[J]. Eur J Clin Invest, 2011, 41(10): 1113-1120.
15. 　Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure[J]. Cochrane Database Syst Rev, 2010, 20(1): CD007893.
16. 　Dehesa L, Abuchar A, Nuno-Gonzalez A, et al. The use of cyclosporine in dermatology[J]. J Drug Dermatol, 2012, 11(8): 979.
17. 　Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference[J]. J Am Acad Dermatol, 2010, 62(5): 838-853.

Previous Article
Evaluation of Diagnostic Criteria for Disseminated Intravascular Coagulation in Obstetric Patients
Next Article
The Research of the Relationship between Ambient Air Sulfur Dioxide and Allergen

West China Medical Journal

Evidence-based Treatment for Psoriasis Erythroderma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content